Get the Stockscreener App
21.64
3.52%
-0.79
Arcus Biosciences Inc stock is traded at $21.64, with a volume of 4.16M.
It is down -3.52% in the last 24 hours and up +13.95% over the past month.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.
See More
Previous Close:
$22.43
Open:
$22.46
24h Volume:
4.16M
Relative Volume:
3.00
Market Cap:
$2.71B
Revenue:
$247.00M
Net Income/Loss:
$-353.00M
P/E Ratio:
-6.557
EPS:
-3.3003
Net Cash Flow:
$-484.00M
1W Performance:
-1.50%
1M Performance:
+13.95%
6M Performance:
+74.66%
1Y Performance:
+138.59%
1-Day Range:
$21.64
$22.75
1-Week Range:
$21.64
$23.16
52-Week Range:
$6.50
$26.40
Arcus Biosciences Inc Stock (RCUS) Company Profile
Name
Arcus Biosciences Inc
Sector
Industry
Phone
(510) 694-6200
Address
3928 POINT EDEN WAY, HAYWARD, CA
Compare RCUS vs VRTX, REGN, ALNY, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
21.64 | 2.71B | 247.00M | -353.00M | -484.00M | -3.3003 |
VRTX
Vertex Pharmaceuticals Inc
|
454.00 | 115.33B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
732.87 | 77.48B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
312.17 | 41.40B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
663.93 | 41.09B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
275.28 | 30.56B | 5.36B | 287.73M | 924.18M | 2.5229 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-26 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-13-26 | Upgrade | Goldman | Neutral → Buy |
| Jan-08-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-26-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-21-24 | Initiated | H.C. Wainwright | Neutral |
| Oct-08-24 | Initiated | Wells Fargo | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Neutral |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Nov-24-20 | Initiated | Berenberg | Buy |
| Nov-23-20 | Initiated | Evercore ISI | Outperform |
| Apr-03-20 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Sep-27-19 | Initiated | Mizuho | Buy |
| May-24-19 | Resumed | Citigroup | Buy |
| Oct-09-18 | Initiated | Wedbush | Outperform |
| Apr-09-18 | Initiated | Citigroup | Buy |
| Apr-09-18 | Initiated | Goldman | Neutral |
| Apr-09-18 | Initiated | Leerink Partners | Outperform |
View All
Arcus Biosciences Inc Stock (RCUS) Latest News
(RCUS) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Arcus Biosciences, Inc. (RCUS) Stock Price Prediction for 2026, 2030-2040 - Traders Union
B of A Securities Maintains Arcus Biosciences (RCUS) Neutral Recommendation - MSN
Arcus Biosciences, Inc. $RCUS Shares Bought by Decheng Capital LLC - MarketBeat
Here’s what analysts think about Arcus Biosciences (RCUS) - MSN
WINTON GROUP Ltd Purchases Shares of 92,229 Arcus Biosciences, Inc. $RCUS - MarketBeat
Why Arcus Biosciences (RCUS) Is Up 9.5% After New Casdatifan Data And Pipeline Expansion - simplywall.st
Arcus Biosciences (RCUS) Valuation After Casdatifan Kidney Cancer Data Pipeline Update And Earnings - Sahm
How (RCUS) Movements Inform Risk Allocation Models - Stock Traders Daily
New Arcus Biosciences hires receive stock options at $23.43 - Stock Titan
Arcus Biosciences at Leerink Conference: Casdatifan’s Promising Data By Investing.com - Investing.com Canada
RCUS: Casdatifan delivers higher efficacy and durable responses in RCC, with strong upcoming trial data - TradingView
Is Arcus Biosciences Inc still a buy after recent gainsWeekly Trading Summary & Comprehensive Market Scan Insights - baoquankhu1.vn
Performance Recap: Can Arcus Biosciences Inc disrupt its industryJuly 2025 Macro Moves & Scalable Portfolio Growth Methods - baoquankhu1.vn
Vanguard Group Inc. Increases Stock Holdings in Arcus Biosciences, Inc. $RCUS - MarketBeat
Aug Sectors: Is Arcus Biosciences Inc in a long term uptrendQuarterly Performance Summary & Free High Return Stock Watch Alerts - baoquankhu1.vn
Citigroup Raises Arcus Biosciences (RCUS) Price Target to $45 | - GuruFocus
Citigroup Raises Arcus Biosciences (NYSE:RCUS) Price Target to $45.00 - MarketBeat
Fisher Asset Management LLC Acquires 640,990 Shares of Arcus Biosciences, Inc. $RCUS - MarketBeat
RCUS SEC FilingsArcus Bioscience 10-K, 10-Q, 8-K Forms - Stock Titan
Arcus (RCUS) Q4 2025 Earnings Call Transcript - AOL.com
RCUS Stock Jumps 17.5% Despite $353M Net Loss: What $34 Fair Value Signals - TIKR.com
Arcus Biosciences (RCUS) Is Up 27.0% After Casdatifan Kidney Cancer Data And TKI-Free Strategy Shift - simplywall.st
The Analyst Verdict: Arcus Biosciences In The Eyes Of 5 Experts - Sahm
Arcus Biosciences: Q4 Beat And Casdatifan’s Story So Far (NYSE:RCUS) - Seeking Alpha
RCUS Analyst Rating Updated by Leerink Partners | RCUS Stock New - GuruFocus
Arcus Biosciences (NYSE:RCUS) Stock Price Expected to Rise, Leerink Partners Analyst Says - MarketBeat
Arcus Biosciences (NYSE:RCUS) Shares Up 9.5%Here's What Happened - MarketBeat
Arcus Biosciences (NYSE:RCUS) Given "Buy" Rating at HC Wainwright - MarketBeat
Arcus Biosciences Puts Casdatifan Kidney Cancer Data At Center Stage - Yahoo Finance
Arcus Biosciences (RCUS) Analyst Rating Reaffirmed with Target P - GuruFocus
HC Wainwright Brokers Increase Earnings Estimates for RCUS - MarketBeat
Performance Recap: Is Arcus Biosciences Inc stock a buy or sellEarnings Miss & Community Consensus Trade Alerts - baoquankhu1.vn
Can Arcus Biosciences Inc stock double in the next year2025 Growth vs Value & Accurate Technical Buy Alerts - baoquankhu1.vn
Assessing Arcus Biosciences (RCUS) Valuation After Recent Share Price Rebound And Casdatifan Expectations - simplywall.st
Arcus Biosciences Q4 Earnings Call Highlights - Yahoo Finance
Arcus Biosciences (RCUS) Posts US$106 Million Q4 Loss Reinforcing Bearish Profitability Narratives - Sahm
Arcus Biosciences, Inc. (NYSE:RCUS) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Arcus Biosciences, Inc. 2025 Q4ResultsEarnings Call Presentation (NYSE:RCUS) 2026-02-27 - Seeking Alpha
Arcus Biosciences (RCUS) Stock Analysis: Is A 65% Upside In Reach? - DirectorsTalk Interviews
MRGPRX2 antagonists disclosed in Arcus Biosciences patent - BioWorld MedTech
FY2030 Earnings Estimate for RCUS Issued By HC Wainwright - MarketBeat
Trading Systems Reacting to (RCUS) Volatility - Stock Traders Daily
Cancer and immune drug developer Arcus Biosciences offers March webcast - Stock Titan
Is Arcus Biosciences (RCUS) Pricing Reflect Its 1‑Year Surge And Mixed Valuation Signals - simplywall.st
Arcus Biosciences, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Arcus Biosciences earnings beat by $0.21, revenue fell short of estimates - Investing.com Canada
Arcus Biosciences Inc (RCUS) Q4 2025 Earnings Call Highlights: S - GuruFocus
Decoding Arcus Biosciences Inc (RCUS): A Strategic SWOT Insight - GuruFocus
Arcus Biosciences Q4 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Arcus Biosciences beats EPS expectations in Q4 2025 - Investing.com Nigeria
Arcus Biosciences Inc Stock (RCUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):